Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II

OBJECTIVE: To evaluate the efficacy of ubrogepant on patient‐reported functional disability, satisfaction with study medication, and global impression of change. BACKGROUND: Ubrogepant is a small‐molecule, oral calcitonin gene‐related peptide receptor antagonist indicated for the acute treatment of...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodick, David W., Lipton, Richard B., Ailani, Jessica, Halker Singh, Rashmi B., Shewale, Anand R., Zhao, Sihui, Trugman, Joel M., Yu, Sung Yun, Viswanathan, Hema N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155006/
https://www.ncbi.nlm.nih.gov/pubmed/32073660
http://dx.doi.org/10.1111/head.13766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155006/
https://www.ncbi.nlm.nih.gov/pubmed/32073660
http://dx.doi.org/10.1111/head.13766

Ejemplares similares